LABP-73: A Novel NLRX1 Ligand for the Treatment of Chronic Asthma

Abstract

NLRX1 is a negative regulatory NOD-like receptor that has previously been shown to be protective against multiple respiratory diseases, including chronic obstructive pulmonary disease and fungal challenge with Aspergillus fumigatus. Activation of NLRX1, with the orally-active, gut-restricted first-in-class therapeutic, NX-13, has previously demonstrated an ability to control immunometabolism and to reduce Th17 differentiation and neutrophil recruitment while providing a favorable tolerability profile in the context of inflammatory bowel disease.